LBF20407LX01 - Revision history

Editor at 00:00, 21 January 2014

2014-01-21T00:00:00Z

@@ Line 19: / Line 19: @@
 |Symbol=LXA4
 |Biological Activity=LXA is equipotent to LTB in inducing superoxide generation in human neutrophils (0.1 mu M) [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335|{{RelationTable/GetFirstAuthor|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis promotion, natural killer cell inhibition, and monocyte migration and adhesion [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335|{{RelationTable/GetFirstAuthor|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]][[Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266|{{RelationTable/GetFirstAuthor|Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266}}]][[Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137|{{RelationTable/GetFirstAuthor|Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137}}]]. Lipoxin A4 is either vasoconstrictive or vasodilatory, and has immunoregulatory activities blocking the cytotoxic action of NK cell, inhibiting adherence and chemotaxis of leukocytes induced by FMLP, PAF or leukotriene B4[[Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1|{{RelationTable/GetFirstAuthor|Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1}}]]<!--0035-->.
 }}
 {{Lipid/Footer}}

Yoshimoto at 04:18, 20 January 2014

2014-01-20T04:18:55Z

← Older revision		Revision as of 13:18, 20 January 2014
Line 9:		Line 9:
	\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) -eicosatetraenoic acid		\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) -eicosatetraenoic acid
	\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&		\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&
	\|Solubility=diethyl ether, methanol. [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]		\|Solubility=diethyl ether, methanol. [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]<!--1037-->
	\|UV Spectra=lambda max: 302nm epsilon : 50,000, lambda MeOHmax: 287,301 (epsilon 50,000) , 316nm [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]], [[Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340}}]]		\|UV Spectra=lambda max: 302nm epsilon : 50,000, lambda MeOHmax: 287,301 (epsilon 50,000) : 316nm [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]<!--1037-->, [[Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340}}]]<!--1038-->
	\|NMR Spectra=^1 H-NMR(250MHz, 5% CD3OD/D2O ) : delta 0.8-0.9(brt, 3H), 1.2-1.8(m, 14H), 2.1-2.3(m, 2H), 3.4-3.6(m, 1H), 3.95-4.05(t, J=6.8Hz, 1H), 4.1-4.2(q, J=7.1Hz, 1H), 5.6-5.85(seven lines, 2H), 5.9-6.1(m, 2H), 6.2-6.45(m, 2H), 6.6-6.8(m, 2H). [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]		\|NMR Spectra=^1 H-NMR(250MHz, 5% CD3OD/D2O ) : delta 0.8-0.9(brt, 3H), 1.2-1.8(m, 14H), 2.1-2.3(m, 2H), 3.4-3.6(m, 1H), 3.95-4.05(t, J=6.8Hz, 1H), 4.1-4.2(q, J=7.1Hz, 1H), 5.6-5.85(seven lines, 2H), 5.9-6.1(m, 2H), 6.2-6.45(m, 2H), 6.6-6.8(m, 2H). [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]<!--1037-->
	\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].		\|Mass Spectra=TMS-derivs. ; 582(M^+ ), 492, 482, 379, 289, 203, 173, 171. [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Biochem._Biophys._Res._Commun.,1984,118,943\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Biochem._Biophys._Res._Commun.,1984,118,943}}]]<!--1036-->
	\|Chemical Synthesis=		\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. Lipoxin A4 is produced by activated leukocytes [[Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1}}]]<!--0035-->, [[Reference:Brady_HR:Serhan_CN:,Curr._Opin._Nephrol._Hypertens.,1996,5,20\|{{RelationTable/GetFirstAuthor\|Reference:Brady_HR:Serhan_CN:,Curr._Opin._Nephrol._Hypertens.,1996,5,20}}]]<!--0036-->.
	\|Metabolism=		\|Chemical Synthesis=[http://lipidbank.jp/image/XPR4001FT0001.gif Table0001] [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]<!--1037-->
			\|Metabolism=Dual lipoxygenation pathways are considered for lipoxin A4 synthesis from arachidonic acid; either 15-lipoxygenase and 5-lipoxygenase in leukocytes or 5-lipoxygenase in leukocytes and 12-lipoxygenase in platelets [[Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1}}]]<!--0035-->.
			\|Genetic Information=cDNA for a receptor specific for lipoxin A4 was cloned out of orphan cDNAs [[Reference:Fiore_S:Maddox_JF:Perez_HD:Serhan_CN:,J._Exp._Med.,1994,180,253\|{{RelationTable/GetFirstAuthor\|Reference:Fiore_S:Maddox_JF:Perez_HD:Serhan_CN:,J._Exp._Med.,1994,180,253}}]]<!--0037-->.
	\|Symbol=LXA4		\|Symbol=LXA4
	\|Biological Activity=LXA is equipotent to LTB in inducing superoxide generation in human neutrophils (0.1 mu M) [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis promotion, natural killer cell inhibition, and monocyte migration and adhesion [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]][[Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266\|{{RelationTable/GetFirstAuthor\|Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266}}]][[Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137\|{{RelationTable/GetFirstAuthor\|Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137}}]]. Lipoxin A4 is either vasoconstrictive or vasodilatory, and has immunoregulatory activities blocking the cytotoxic action of NK cell, inhibiting adherence and chemotaxis of leukocytes induced by FMLP, PAF or leukotriene B4[[Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1}}]].		\|Biological Activity=LXA is equipotent to LTB in inducing superoxide generation in human neutrophils (0.1 mu M) [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis promotion, natural killer cell inhibition, and monocyte migration and adhesion [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]][[Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266\|{{RelationTable/GetFirstAuthor\|Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266}}]][[Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137\|{{RelationTable/GetFirstAuthor\|Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137}}]]. Lipoxin A4 is either vasoconstrictive or vasodilatory, and has immunoregulatory activities blocking the cytotoxic action of NK cell, inhibiting adherence and chemotaxis of leukocytes induced by FMLP, PAF or leukotriene B4[[Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1}}]]<!--0035-->.
	}}		}}

	{{Lipid/Footer}}		{{Lipid/Footer}}

Yoshimoto at 03:42, 20 January 2014

2014-01-20T03:42:51Z

← Older revision		Revision as of 12:42, 20 January 2014
Line 11:		Line 11:
	\|Solubility=diethyl ether, methanol. [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]		\|Solubility=diethyl ether, methanol. [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]
	\|UV Spectra=lambda max: 302nm epsilon : 50,000, lambda MeOHmax: 287,301 (epsilon 50,000) , 316nm [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]], [[Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340}}]]		\|UV Spectra=lambda max: 302nm epsilon : 50,000, lambda MeOHmax: 287,301 (epsilon 50,000) , 316nm [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]], [[Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340}}]]
			\|NMR Spectra=^1 H-NMR(250MHz, 5% CD3OD/D2O ) : delta 0.8-0.9(brt, 3H), 1.2-1.8(m, 14H), 2.1-2.3(m, 2H), 3.4-3.6(m, 1H), 3.95-4.05(t, J=6.8Hz, 1H), 4.1-4.2(q, J=7.1Hz, 1H), 5.6-5.85(seven lines, 2H), 5.9-6.1(m, 2H), 6.2-6.45(m, 2H), 6.6-6.8(m, 2H). [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]
	\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].		\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].
	\|Chemical Synthesis=		\|Chemical Synthesis=

Yoshimoto at 03:39, 20 January 2014

2014-01-20T03:39:05Z

← Older revision		Revision as of 12:39, 20 January 2014
Line 9:		Line 9:
	\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) -eicosatetraenoic acid		\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) -eicosatetraenoic acid
	\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&		\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&
			\|Solubility=diethyl ether, methanol. [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]
	\|UV Spectra=lambda max: 302nm epsilon : 50,000, lambda MeOHmax: 287,301 (epsilon 50,000) , 316nm [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]], [[Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340}}]]		\|UV Spectra=lambda max: 302nm epsilon : 50,000, lambda MeOHmax: 287,301 (epsilon 50,000) , 316nm [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]], [[Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340}}]]
	\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].		\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].

Yoshimoto at 03:34, 20 January 2014

2014-01-20T03:34:31Z

← Older revision		Revision as of 12:34, 20 January 2014
Line 9:		Line 9:
	\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) -eicosatetraenoic acid		\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) -eicosatetraenoic acid
	\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&		\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&
	\|UV Spectra=lambda max: 302nm epsilon : 50,000		\|UV Spectra=lambda max: 302nm epsilon : 50,000, lambda MeOHmax: 287,301 (epsilon 50,000) , 316nm [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]], [[Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340}}]]
	\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].		\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].
	\|Chemical Synthesis=		\|Chemical Synthesis=

Yoshimoto at 03:26, 20 January 2014

2014-01-20T03:26:17Z

← Older revision		Revision as of 12:26, 20 January 2014
Line 14:		Line 14:
	\|Metabolism=		\|Metabolism=
	\|Symbol=LXA4		\|Symbol=LXA4
	\|Biological Activity=LXA is equipotent to LTB in inducing superoxide generation in human neutrophils (0.1 mu M) [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis promotion, natural killer cell inhibition, and monocyte migration and adhesion [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]][[Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266\|{{RelationTable/GetFirstAuthor\|Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266}}]][[Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137\|{{RelationTable/GetFirstAuthor\|Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137}}]]. Lipoxin A4 is either vasoconstrictive or vasodilatory, and has immunoregulatory activities blocking the cytotoxic action of NK cell, inhibiting adherence and chemotaxis of leukocytes induced by FMLP, PAF or leukotriene B4[[~~Reference:~~Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1}}]].		\|Biological Activity=LXA is equipotent to LTB in inducing superoxide generation in human neutrophils (0.1 mu M) [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis promotion, natural killer cell inhibition, and monocyte migration and adhesion [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]][[Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266\|{{RelationTable/GetFirstAuthor\|Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266}}]][[Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137\|{{RelationTable/GetFirstAuthor\|Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137}}]]. Lipoxin A4 is either vasoconstrictive or vasodilatory, and has immunoregulatory activities blocking the cytotoxic action of NK cell, inhibiting adherence and chemotaxis of leukocytes induced by FMLP, PAF or leukotriene B4[[Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1}}]].
	}}		}}

	{{Lipid/Footer}}		{{Lipid/Footer}}

Yoshimoto at 03:24, 20 January 2014

2014-01-20T03:24:57Z

← Older revision		Revision as of 12:24, 20 January 2014
Line 14:		Line 14:
	\|Metabolism=		\|Metabolism=
	\|Symbol=LXA4		\|Symbol=LXA4
	\|Biological Activity=LXA is equipotent to LTB in inducing superoxide generation in human neutrophils (0.1 mu M) [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis promotion, natural killer cell inhibition, and monocyte migration and adhesion [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]][[Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266\|{{RelationTable/GetFirstAuthor\|Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266}}]][[Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137\|{{RelationTable/GetFirstAuthor\|Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137}}]].		\|Biological Activity=LXA is equipotent to LTB in inducing superoxide generation in human neutrophils (0.1 mu M) [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]]. LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis promotion, natural killer cell inhibition, and monocyte migration and adhesion [[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]][[Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266\|{{RelationTable/GetFirstAuthor\|Reference:Ramstedt_U:Serhan_CN:Nicolaou_KC:Webber_SE:Wigzell_H:Samuelsson_B:,J. Immunol.,1987,138,266}}]][[Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137\|{{RelationTable/GetFirstAuthor\|Reference:Maddox_JF:Serhan_CN:,J. Exp. Med.,1996,183,137}}]]. Lipoxin A4 is either vasoconstrictive or vasodilatory, and has immunoregulatory activities blocking the cytotoxic action of NK cell, inhibiting adherence and chemotaxis of leukocytes induced by FMLP, PAF or leukotriene B4[[Reference:Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:,Biochim._Biophys._Acta,1994,1212,1}}]].
	}}		}}

	{{Lipid/Footer}}		{{Lipid/Footer}}

Yoshimoto at 07:08, 17 January 2014

2014-01-17T07:08:06Z

← Older revision		Revision as of 16:08, 17 January 2014
Line 7:		Line 7:
	\|LipidMaps=LMFA03040001		\|LipidMaps=LMFA03040001
	\|CAS=89663-86-5		\|CAS=89663-86-5
	\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) - eicosatetraenoic acid		\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) -eicosatetraenoic acid
	\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&		\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&
	\|UV Spectra=lambda max: 302nm epsilon : 50,000		\|UV Spectra=lambda max: 302nm epsilon : 50,000

Yoshimoto at 05:51, 17 January 2014

2014-01-17T05:51:47Z

← Older revision		Revision as of 14:51, 17 January 2014
Line 4:		Line 4:

	{{Metabolite		{{Metabolite
	\|LipidBank=~~DFA815~~		\|LipidBank=DFA8153
	\|LipidMaps=LMFA03040001		\|LipidMaps=LMFA03040001
	\|CAS=89663-86-5		\|CAS=89663-86-5
	\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) - eicosatetraenoic acid		\|SysName=(5S,6R,15S) -Trihydroxy- (trans-7,trans-9,cis-11,trans-13) - eicosatetraenoic acid
	\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&		\|Common Name=&&Lipoxin A_4&&(5S,6R,15S) -Trihydroxy- (7E,9E,11Z,13E) -eicosatetraenoic acid&&
	\|UV Spectra= lambda max: 302nm epsilon : 50,000		\|UV Spectra=lambda max: 302nm epsilon : 50,000
	\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].		\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].
	\|Chemical Synthesis=		\|Chemical Synthesis=

Yoshimoto at 05:38, 17 January 2014

2014-01-17T05:38:35Z

← Older revision		Revision as of 14:38, 17 January 2014
Line 4:		Line 4:

	{{Metabolite		{{Metabolite
	\|LipidBank=DFA815~~;XPR4001~~		\|LipidBank=DFA815
	\|LipidMaps=LMFA03040001		\|LipidMaps=LMFA03040001
	\|CAS=89663-86-5		\|CAS=89663-86-5

← Older revision		Revision as of 12:42, 20 January 2014
Line 11:		Line 11:
	\|Solubility=diethyl ether, methanol. [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]		\|Solubility=diethyl ether, methanol. [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]
	\|UV Spectra=lambda max: 302nm epsilon : 50,000, lambda MeOHmax: 287,301 (epsilon 50,000) , 316nm [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]], [[Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340}}]]		\|UV Spectra=lambda max: 302nm epsilon : 50,000, lambda MeOHmax: 287,301 (epsilon 50,000) , 316nm [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]], [[Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Nicolaou_KC:Webber_SE:Veale_CA:Dahlen_SE:Puustinen_TJ:Samuelsson_B:,J._Biol._Chem.,1986,261,16340}}]]
			\|NMR Spectra=^1 H-NMR(250MHz, 5% CD3OD/D2O ) : delta 0.8-0.9(brt, 3H), 1.2-1.8(m, 14H), 2.1-2.3(m, 2H), 3.4-3.6(m, 1H), 3.95-4.05(t, J=6.8Hz, 1H), 4.1-4.2(q, J=7.1Hz, 1H), 5.6-5.85(seven lines, 2H), 5.9-6.1(m, 2H), 6.2-6.45(m, 2H), 6.6-6.8(m, 2H). [[Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464\|{{RelationTable/GetFirstAuthor\|Reference:Adams_J:Fitzsimmons_BJ:Girard_Y:Leblanc_Y:Evans_JF:Rokach_J:,J._Am._Chem._Soc.,1985,107,464}}]]
	\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].		\|Source=LXA4 is formed in vitro by a number of mechanisms from arachidonic acid, 15-HpETE, and leukotriene A4 (LTA4 ) [[Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401\|{{RelationTable/GetFirstAuthor\|Reference:Edenius_C:Stenke_L:Lindgren_JA:,Eur. J. Biochem.,1991,199,401}}]][[Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335\|{{RelationTable/GetFirstAuthor\|Reference:Serhan_CN:Hamberg_M:Samuelsson_B:,Proc. Natl. Acad. Sci. U. S. A.,1984,81,5335}}]].
	\|Chemical Synthesis=		\|Chemical Synthesis=